Background. Live oral rhesus-rhesus-human rotavirus reassortant tetravalent (RRV-TV) vaccine was efficacious against rotavirus gastroenteritis but was withdrawn because of a rare association with intussusception. A corresponding tetravalent (types G1, G2, G3, and G4) reassortant vaccine based on bovine-human (UK) rotavirus reassortant tetravalent (BRV-TV) vaccine was developed concurrently.
million doses of the vaccine were administered in the United States until July 1999, when its use was suspended because of a suspected association with intussusception [1] . Later the same year, the RotaShield vaccine was withdrawn by the manufacturer [2] , and it has not been used since. The reintroduction of RotaShield by another manufacturer remains a possibility [3] .
Before intussusception became an issue, RotaShield was regarded as safe, but its association with febrile reactions, typically 3-4 days after the administration of the first dose, was seen as a problem, at least in some populations. In Finland, administration of the first dose of vaccine at the age of 2-3 months was associated with fever (temperature, у38.0ЊC) in 33% of vaccinees and with a high fever (temperature, у39.0ЊC) in 3.4% of vaccinees [4, 5] . Such high reactogenicity correlated with low levels of preexisting rotavirus antibody in Finnish infants, compared with those in Venezuelan infants, where febrile reactions were mild and were seen in only 15% of vaccinees [6, 7] .
In contrast to rhesus rotavirus, bovine rotavirus candidate vaccines, such as RIT4237 and WC3, were not associated with febrile reactions [8] [9] [10] . The development of bovine rotavirus vaccine RIT4237 was discontinued, and that of the WC3 vaccine was only later resumed as a reassortant vaccine [11] .
Meanwhile, the UK strain of bovine rotavirus was reassorted with human rotavirus G types 1, 2, 3, or 4, for the development of a tetravalent vaccine, at the same laboratory where the RRV-TV vaccine had originated and was evaluated in phase 2 trials [12] [13] [14] [15] . The bovine-human (UK) rotavirus reassortant tetravalent (BRV-TV) vaccine was developed by Wyeth in collaboration with the US National Institute of Allergy and Infectious Diseases (NIAID) and is considered to be a possible future alternative for RRV-TV vaccine, because of its lower reactogenicity.
The present study, which began in 1997, was conducted to evaluate and compare the reactogenicity, immunogenicity, and efficacy of 2 doses of RRV-TV and BRV-TV vaccines in Finnish infants who were 2-3 and 4-5 months old at the first and the second dose, respectively. Because of different formulations, each vaccine was compared with its own placebo, and the 2 trials were run in parallel at 2 different locations in Finland.
SUBJECTS AND METHODS
The study protocol was approved by the ethics committees of the Tampere University Hospital District, the City of Lahti Health Department, and the Clinical Research Committee of the NIAID. Before an infant was enrolled in the study, a parent provided written, informed consent, witnessed by a study nurse. The study was conducted between September 1997 and June 1999.
Each vaccine was tested against its own placebo, randomized at a ratio of 2:1 for vaccine:placebo. The RRV-TV vaccine was tested predominantly in the city of Lahti, and the BRV-TV vaccine was tested predominantly in the city of Tampere; the 2 cities are located ∼130 km apart. The planned sample size was 170 for each vaccine and 85 for each placebo, for a total of 510 children.
The RRV-TV vaccine and its placebo were supplied by Wyeth in identical-looking single-dose glass vials. The vaccine titer was pfu: pfu for each monovalent component 5 5 4 ϫ 10 1 ϫ 10 (rhesus-human rotavirus reassortants for types G1, G2, and G4, and rhesus rotavirus for G3), as in the RotaShield product. The placebo consisted of Eagle MEM (EMEM) with sucrose, phosphate, and glutamate (SPG). The vials were labeled with a sequential randomized subject number to which the enrolled infants were assigned. Therefore, the trial of RRV-TV vaccine versus placebo was double blinded. A buffered diluent for RRV-TV vaccine and its placebo was supplied in plastic dispettes in foil pouches, as for the RotaShield product. After reconstitution, the full content of the mixed product (∼2.5 mL) was withdrawn into the plastic dispette for oral administration. There were no feeding restrictions before or after vaccination.
The BRV-TV vaccine was supplied as blocks of four 1-mL vials, each of which contained a monovalent vaccine (final passages in FRhL2 cells) with titers as follows: G1, pfu; 5 6.25 ϫ 10 G2, pfu; G3, pfu; and G4, pfu.
2 ϫ 10 2.25 ϫ 10 6.05 ϫ 10 The corresponding placebo (EMEM and SPG) was also supplied as blocks of four 1-mL vials. The vaccine and placebo were prepared and supplied frozen by DynCorp. All vials (in blocks of 4) were labeled with a sequential randomized subject number to which the enrolled infants were assigned. The contents of each vial was mixed together and administered into the mouth with a syringe. Before administration, infants drank a minimum of 30 mL of soy milk buffered with 400 mg of sodium bicarbonate. The person who mixed the BRV-TV vaccine and placebo vials did not administer the vaccine; therefore, the BRV-TV vaccine versus placebo trial was observer blinded.
The vaccinations were administered at dedicated vaccine research clinics of the University of Tampere in Tampere and Lahti, respectively. Only healthy infants at a gestational age of у37 weeks were enrolled. For the first dose of rotavirus vaccine or placebo, other vaccinations were not allowed within 1 week after administration of the study vaccine or placebo. For the second dose of rotavirus vaccine or placebo at 4-5 months of age, concomitant routine immunizations (with diphtheria-tetanus toxoid-pertussis [DTP] vaccine and Haemophilus influenzae type b [Hib] vaccine) were allowed. The recruitment period for the first dose was from September to early December 1997-that is, before the rotavirus epidemic season.
During the 7-day period after vaccination, parents recorded all events on a diary card. Rectal temperatures were measured each day at the same time or whenever the child appeared to have a fever. Parents also recorded episodes of vomiting and irritability. All stools were recorded and graded as normal or looser than normal. To enforce compliance, a phone call was made on day 5 after each dose.
Venous blood samples were collected before the first immunization and ∼1 month (range, 21-41 days) after the second immunization. Serum samples were separated, aliquoted into 2 samples, and stored frozen until analysis. One aliquot was used for the determination of serum rotavirus IgA antibodies by ELISA at the University of Tampere, as described elsewhere [16] . The other aliquot was shipped on dry ice to the Laboratory of Infectious Diseases, NIAID, for the determination of levels of rotavirus neutralizing antibodies. Levels of antibodies against each serotype of human rotaviruses G1-G4, RRV (G3), and BRV (G6) were measured under code, using a plaque-reduction neutralization assay described elsewhere [17] .
Efficacy follow-up started on the fifteenth day after the second immunization. Follow-up for the first rotavirus season ended on 30 June 1998. The follow-up was resumed on 1 December 1998 and continued for the second rotavirus epidemic season, until the end of June 1999. During each followup period, parents received biweekly reminder phone calls from study nurses. Whenever a child developed diarrhea, parents contacted the study nurse and started a diary card recording rectal temperature, vomiting, diarrhea, and use of oral rehydration therapy until the episode resolved; the information was used to evaluate the severity of episodes according to a numerical score described elsewhere [18] . Stool samples were obtained from all infants with gastroenteritis. The samples were kept frozen at Ϫ20ЊC until they were shipped to the University of Tampere Medical School for rotavirus studies. Rotavirus was primarily detected using an ELISA (Rotazyme; Dako). All positive samples were confirmed and G-typed using a reversetranscriptase polymerase chain reaction assay [19] .
Postvaccination fever (rectal temperature, у38.0ЊC) was the primary safety parameter in the study. The analysis plan for fever specified a comparison of fever rates in infants who received placebo between the 2 sites. If not significantly different ( ), infants who received placebo would be combined. P 1 .20 After each vaccination, the incidence of fever for the 7-day follow-up period was summarized, and the rates were compared using Fisher's exact test. The sample size was designed with 80% power to detect a difference in the rate of fever between BRV-TV and RRV-TV vaccine of 15% versus 30%.
For immunogenicity, seroconversion by rotavirus IgA was determined as a change from negative to positive (у20 U) [16] , and the seroresponse for neutralizing antibodies against each of the G types in the reassortants vaccines was defined as a у4-fold increase. Comparison of seroresponders was done using Fisher's exact test.
The primary efficacy end point was any episode of rotavirusassociated gastroenteritis. The sample size was calculated to have 80% power to detect vaccine efficacy if the true efficacy was 70%. The efficacy of each vaccine was determined on the basis of the relative risk (RR) between the vaccine group and its placebo group. Vaccine efficacy was calculated as , 1 Ϫ RR where the RR was the ratio of the percentage of infants in the vaccine group with the event divided by the percentage of infants in the placebo group who developed gastroenteritis. Confidence limits for RRs were calculated using exact methods as implemented in StatXact software (version 6; Cytel Software). Comparisons were done using Fisher's exact test.
RESULTS
In Tampere, BRV-TV vaccine was given to 172 infants, and its placebo was given to 86 infants. Dose 1 was given at a mean age of 95 days (range, 58-122 days), and dose 2 was given at a mean age of 150 days (range, 86-192 days).
In Lahti, RRV-TV vaccine was given to 151 infants, and its placebo was given to 75 infants. Dose 1 was given at a mean age of 86 days (range, 50-122 days), and dose 2 was given at a mean age of 135 days (range, 78-180 days). Because recruitment in Lahti was slower than that in Tampere and the rotavirus epidemic season was approaching, the last 15 infants in the RRV-TV vaccine group were vaccinated in Tampere (10 received RRV-TV vaccine, and 5 received placebo). Data from these infants are included in the safety and immunogenicity evaluation but not in the efficacy analysis. In the safety and immunogenicity analyses, the vaccine recipients were compared with pooled placebo recipients at both sites. To justify pooling, placebo recipients in Lahti and Tampere were compared with each other for reported fever. The rates of reported fever during the first week after placebo vaccination were 12.5% and 12.2% in Lahti and Tampere, respectively (combined rate, 12.3%) (table 1); after the second placebo dose, the corresponding fever rates were 49.1% and 53.6% (combined rate, 51.6%). The striking increase in fever after the second dose most likely occurred because of the administration of DTP vaccine at the regular well-baby clinics during the same period.
Safety. Rates of fever after vaccination are shown in table 1. Almost one-half of the RRV-TV vaccine recipients had a fever of у38.0ЊC during the week after the first vaccination, versus 12.3% of the combined placebo recipients ( ). P ! .0001 The rate of fever in the BRV-TV vaccine recipients (16.1%) was not significantly different from that in the placebo group, whereas the difference between the RRV-TV and BRV-TV vaccinees was highly significant ( ). The high rate of febrile P ! .0001 reactions after the administration of RRV-TV vaccine was substantiated by a high rate of use of antipyretics: 46.3% of the RRV-TV vaccine recipients were treated with antipyretics during the week after the first vaccination, versus 6.9% BRV-TV vaccine recipients (
). Symptoms other than fever were P ! .0001 not markedly different between the recipients of the RRV-TV and BRV-TV vaccines (table 1) . Most notably, there was no difference in the rate of diarrhea during the week after the first vaccination, which indicates that neither vaccine caused diarrhea in the recipients.
Two infants were withdrawn from the study as a consequence of a vaccine-related adverse event (both had received the RRV-TV vaccine). One child had a febrile reaction starting 3 days after the first dose of RRV-TV vaccine that lasted for 2 days, and another had unusual irritability starting 1 day after vaccination. In addition, there were a total of 14 adverse events after the administration of the first dose of study vaccine that were deemed (while coded) to be "definitely related" to the vaccination by the investigator. All events started on days 2-4 after dosing; were fever, irritability, or both; and lasted 1-4 days. When subject numbers were decoded, it was found that all 14 infants had received the RRV-TV vaccine.
Immunogenicity. Both vaccines were immunogenic after 2 Seroresponses to human VP7 antigens were much less frequent than those to RRV or BRV. Neutralizing antibody responses to human G1 were seen in 48.7% of the BRV-TV and 23.6% of the RRV-TV vaccine recipients, respectively (P ! ), whereas responses to G2 were observed in 35% of the .0001 RRV-TV and 12% of the BRV-TV vaccine recipients (P ! ). Responses to G3 and G4 were not significantly different .0001 between the vaccinated groups. A seroresponse by any test was detected in 2.0% of the placebo recipients, which indicates that intercurrent natural rotavirus infections were uncommon during the vaccination period.
Efficacy. There were a total of 65 episodes of acute gastroenteritis in infants who were positive by EIA for rotavirus during the entire efficacy follow-up. Of these, 48 episodes occurred during the first epidemic season, and 17 occurred during the second epidemic season. Sixty of 65 rotavirus EIA-positive samples from infants with gastroenteritis were from infants who had received 2 doses of vaccine according to study protocol; they formed the PP population. Of the 60 rotavirus EIA-positive samples from infants with acute gastroenteritis in the PP population 54 (90%) were of G1, 1 (2%) was of G2, 2 (3%) were of G3, and 3 (5%) were of G4. Vaccine efficacy against rotavirus gastroenteritis in the PP population is presented in tables 3 and 4. Vaccine efficacy in the entire (intent-to-treat [ITT]) population was similar to that in the PP population (presented below).
During the first rotavirus epidemic season, the efficacy of the BRV-TV vaccine was 69% against any, 79% against moderately severe and severe, and 88% against severe rotavirus gastroenteritis. The efficacy of the RRV-TV vaccine during the first rotavirus epidemic season was 68% against any, 94% against moderately severe and severe, and 100% against severe rotavirus gastroenteritis. The difference in the efficacy of each vaccine at each end point was statistically significant (table 3) .
During the second rotavirus epidemic season, neither vaccine showed efficacy against any rotavirus gastroenteritis (data not shown). The point estimates for any rotavirus gastroenteritis were 0% for the BRV-TV vaccine and Ϫ16% for the RRV-TV vaccine, respectively. The point estimates for efficacy were 50% for each vaccine against moderately severe and severe rotavirus gastroenteritis.
Vaccine efficacy against any rotavirus gastroenteritis in the ITT population during the entire follow-up was 59% (95% confidence interval [CI], 20-79) for the BRV-TV vaccine (P p ) and 50% (95% CI, 8-73) for the RRV-TV vaccine ( .013 P p ). Efficacy against rotavirus gastroenteritis with a score of .030 у7 was 73% (95% CI, 31-91) for the BRV-TV vaccine (P p ), and efficacy against rotavirus gastroenteritis with a score .007 of у11 was 90% (95% CI, 35-99) for the BRV-TV vaccine ( ) and 100% (95% CI, 36-100) for the RRV-TV vaccine P p .017 ( ), respectively (data not shown). P p .035
The effect of each rotavirus vaccine on all acute gastroenteritis, rotavirus or not, is presented in table 5. Only the BRV-TV vaccine showed a significant efficacy against all gastroenteritis of any severity. Both vaccines showed a significant efficacy against moderately severe and severe gastroenteritis; that of the BRV-TV vaccine was 53%, and that of the RRV-TV vaccine was 64%.
DISCUSSION
The present study was begun before the RRV-TV vaccine (RotaShield) was licensed and ended only weeks before the association with intussusception became known [1] . After, and as a consequence of, the withdrawal of RotaShield in October 1999, the analysis of study results was delayed.
The present comparative trial of RotaShield with BRV-TV vaccine was designed as 2 parallel studies, because the 2 vaccines could not be studied in a double-blind fashion. The BRV-TV vaccine had previously been shown to be nonreactogenic but immunogenic in children [14, 15] . This was in contrast to the RRV-TV vaccine, which before licensure was already known to frequently cause febrile reactions [5] . The lower reactogenicity of the BRV-TV vaccine was confirmed in a convincing way, given that fever rates after administration of the BRV-TV vaccine were not different from those after the administration of placebo, whereas administration of the first dose of the RRV-TV vaccine was associated with a 36% rate of fever versus placebo during the first week. The low reactogenicity of the BRV-TV vaccine is in accordance with the findings of previous studies of UK bovine vaccine and is in line with the findings of a large number of previous studies of other bovine rotavirusbased vaccines in humans [8] [9] [10] [11] .
Although the rhesus rotavirus [10] and RRV-TV vaccines [4, 5] were known to be reactogenic in the Finnish population, the reactogenicity of the RRV-TV vaccine was lower in the United States [20] [21] [22] and even more so in Latin America [7] . This may have been due to different prevaccination levels of rotavirus antibodies in these populations. Febrile reactions were age dependent and occurred more commonly in older infants, who have lower levels of preexisting acquired rotavirus antibodies [6] . Even in Finland, the RRV-TV vaccine did not cause febrile reactions in neonates, who have higher levels of rotavirus antibodies [23] .
The immunogenicity of both vaccines, as measured by overall antibody response, was excellent and, if anything, was better for the BRV-TV vaccine. One factor contributing to the good immunogenicity of the BRV-TV vaccine might have been the large volume of buffer given before the administration of this vaccine. Both vaccines induced a strong homologous neutralizing antibody response to the animal rotavirus component (VP4) of the vaccine strain and a weaker response to human rotavirus strains G1-G4. The relatively low seroresponse rates to individual G serotypes may have been, in part, the result of technical issues, given that the neutralization test was started, due to low quantities of serum samples, from a dilution of 1: 40. However, the finding also emphasizes that mechanisms other than G type-specific antibodies play an important role in vaccine-induced protection against rotavirus disease.
To our knowledge, the present study is the only efficacy trial of the RRV-TV vaccine to have had a 2-dose schedule-in all of the pivotal prelicensure studies in Finland, the United States, and Venezuela and in Native Americans, the vaccine was administered in 3 doses [4, 7, [20] [21] [22] . In the present study, the efficacy of 2 doses of the RRV-TV vaccine in Finnish infants was approximately the same as that in an efficacy trial of 3 doses of the same vaccine: 68% efficacy against any rotavirus gastroenteritis during the first year after vaccination in both studies [4] . As for the BRV-TV vaccine, the present results with a 2-dose schedule are not different from the recently published efficacy results of 3 doses of a pentavalent (WC3) bovine-human reassortant rotavirus vaccine, which had an efficacy against G1-G4 rotavirus gastroenteritis of any severity of 74.0% (95% confidence interval [CI], 66.8%-79.9%) and against severe G1-G4 rotavirus gastroenteritis of 98.0% (95% CI, 88.3%-100%) [24] . During the second year, the efficacy of each vaccine against mild rotavirus disease waned, but the efficacy against severe rotavirus gastroenteritis may have been sustained, and the number of cases was very small. It has been shown elsewhere [25] that, in Finnish infants, the protective efficacy of the RRV-TV vaccine against severe rotavirus gastroenteritis was maintained even during the third and fourth rotavirus epidemic seasons after vaccination.
At present, it remains uncertain whether the RRV-TV vaccine will be reintroduced. It is now recognized that the risk of intussusception after administration of the RRV-TV vaccine was lower than that estimated at the time of withdrawal of RotaShield; the current estimates are between 1:10,000 and 1: 32,000, or even lower [26] . Moreover, the occurrence of intussusception was apparently dependent on age [27, 28] . To increase the safety of the RRV-TV vaccine, it would seem advisable to restrict vaccinations to infants !60 days of age, with a possible start during the neonatal period [23] . The present results indicate that a shorter schedule with 2 doses of the RRV-TV vaccine would induce an adequate level of protective efficacy.
To our knowledge, this is the first demonstration of protective efficacy of the BRV-TV vaccine; it is therefore an important milestone with regard to the eventual introduction of this rotavirus vaccine. When the present study was conducted, UK bovine-based vaccine was being considered by Wyeth, the manufacturer of RotaShield. More recently, licenses have been granted by the US National Institutes of Health to several prospective manufacturers in the United States, Brazil, China, and India [29, 30] . The present study was a pilot study for proof of concept, because a final formulation of the BRV-TV vaccine was not tested. More important, the present study did not address safety with regard to intussusception, and a much larger study will be required for investigation of this end point. For regulatory reasons, it will be critical to establish a "final" composition of the future UK bovine-human reassortant vaccine, possibly by adding new reassortants, such as G8 or G9 [28] , to conduct the necessary safety and efficacy trials with this formulation.
